Management of severe heart failure

Shinya Hiramitsu, Kenji Miyagishima, Hisashi Kimura, Kazumasa Mori, Kenji Shiino, Akira Yamada, Shigeru Kato, Yasuchika Kato, Shin Ichiro Morimoto, Hitoshi Hishida, Yukio Ozaki

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a β-blocker. The administration of β-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.

Original languageEnglish
Pages (from-to)A36-A41
JournalCirculation Journal
Volume73
Issue numberSUPPL. A
DOIs
Publication statusPublished - 22-07-2009

Fingerprint

Heart Failure
Heart Transplantation
Therapeutics
Transplants
Ventricular Remodeling
Angiotensin Receptor Antagonists
Drug Combinations
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Japan
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Hiramitsu, S., Miyagishima, K., Kimura, H., Mori, K., Shiino, K., Yamada, A., ... Ozaki, Y. (2009). Management of severe heart failure. Circulation Journal, 73(SUPPL. A), A36-A41. https://doi.org/10.1253/circj.CJ-08-1106
Hiramitsu, Shinya ; Miyagishima, Kenji ; Kimura, Hisashi ; Mori, Kazumasa ; Shiino, Kenji ; Yamada, Akira ; Kato, Shigeru ; Kato, Yasuchika ; Morimoto, Shin Ichiro ; Hishida, Hitoshi ; Ozaki, Yukio. / Management of severe heart failure. In: Circulation Journal. 2009 ; Vol. 73, No. SUPPL. A. pp. A36-A41.
@article{05f0388ab2b34f2c93cb232aaa302492,
title = "Management of severe heart failure",
abstract = "Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a β-blocker. The administration of β-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.",
author = "Shinya Hiramitsu and Kenji Miyagishima and Hisashi Kimura and Kazumasa Mori and Kenji Shiino and Akira Yamada and Shigeru Kato and Yasuchika Kato and Morimoto, {Shin Ichiro} and Hitoshi Hishida and Yukio Ozaki",
year = "2009",
month = "7",
day = "22",
doi = "10.1253/circj.CJ-08-1106",
language = "English",
volume = "73",
pages = "A36--A41",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "SUPPL. A",

}

Hiramitsu, S, Miyagishima, K, Kimura, H, Mori, K, Shiino, K, Yamada, A, Kato, S, Kato, Y, Morimoto, SI, Hishida, H & Ozaki, Y 2009, 'Management of severe heart failure', Circulation Journal, vol. 73, no. SUPPL. A, pp. A36-A41. https://doi.org/10.1253/circj.CJ-08-1106

Management of severe heart failure. / Hiramitsu, Shinya; Miyagishima, Kenji; Kimura, Hisashi; Mori, Kazumasa; Shiino, Kenji; Yamada, Akira; Kato, Shigeru; Kato, Yasuchika; Morimoto, Shin Ichiro; Hishida, Hitoshi; Ozaki, Yukio.

In: Circulation Journal, Vol. 73, No. SUPPL. A, 22.07.2009, p. A36-A41.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of severe heart failure

AU - Hiramitsu, Shinya

AU - Miyagishima, Kenji

AU - Kimura, Hisashi

AU - Mori, Kazumasa

AU - Shiino, Kenji

AU - Yamada, Akira

AU - Kato, Shigeru

AU - Kato, Yasuchika

AU - Morimoto, Shin Ichiro

AU - Hishida, Hitoshi

AU - Ozaki, Yukio

PY - 2009/7/22

Y1 - 2009/7/22

N2 - Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a β-blocker. The administration of β-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.

AB - Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a β-blocker. The administration of β-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.

UR - http://www.scopus.com/inward/record.url?scp=67650572121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650572121&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-08-1106

DO - 10.1253/circj.CJ-08-1106

M3 - Review article

C2 - 19474507

AN - SCOPUS:67650572121

VL - 73

SP - A36-A41

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - SUPPL. A

ER -

Hiramitsu S, Miyagishima K, Kimura H, Mori K, Shiino K, Yamada A et al. Management of severe heart failure. Circulation Journal. 2009 Jul 22;73(SUPPL. A):A36-A41. https://doi.org/10.1253/circj.CJ-08-1106